Alnylam Current Deferred Revenue from 2010 to 2024
| ALNY Stock | USD 152.04 0.02 0.01% |
Current Deferred Revenue | First Reported 2003-12-31 | Previous Quarter 102.8 M | Current Value 76.8 M | Quarterly Volatility 81.4 M |
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 60.78. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
Alnylam | Current Deferred Revenue |
Latest Alnylam Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Alnylam Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Alnylam Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Alnylam Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 129,496,981 | |
| Geometric Mean | 62,910,136 | |
| Coefficient Of Variation | 94.07 | |
| Mean Deviation | 88,620,143 | |
| Median | 84,780,000 | |
| Standard Deviation | 121,813,306 | |
| Sample Variance | 14838.5T | |
| Range | 395.9M | |
| R-Value | 0.36 | |
| Mean Square Error | 13886.3T | |
| R-Squared | 0.13 | |
| Significance | 0.18 | |
| Slope | 9,859,043 | |
| Total Sum of Squares | 207738.7T |
Alnylam Current Deferred Revenue History
About Alnylam Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Alnylam Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Alnylam Pharmaceuticals investors use historical funamental indicators, such as Alnylam Pharmaceuticals's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Alnylam Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Alnylam Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alnylam Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alnylam Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 102.8 M | 119.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| COST | Costco Wholesale Corp | |
| AMZN | Amazon Inc | |
| AVGO | Broadcom |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.